A Randomized Trial of Celecoxib and Rosiglitazone, Alone and in Combination, in Patients With Early Stage Non-Invasive Bladder Carcinoma Undergoing Cystoscopic Surveillance and in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Celecoxib (Primary) ; Rosiglitazone (Primary)
- Indications Bladder cancer
- Focus Biomarker; Pharmacodynamics
- 15 Jul 2013 Biomarkers information updated
- 01 Apr 2009 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Aug 2005 New trial record.